Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2

Rheumatology (United Kingdom)

Volumn 51, Issue 7, 2012, Pages 1181-1187

  Ishikawa, Asuka ^a   Muro, Yoshinao ^a   Sugiura, Kazumitsu ^a   Akiyama, Masashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti MJ antibody; Anti NXP 2 antibody; Dermatomyositis; ELISA; Myositis specific autoantibody

Indexed keywords

AUTOANTIBODY; NUCLEAR MATRIX PROTEIN 22; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOTINYLATION; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; JAPANESE; JUVENILE DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MYOSITIS; OVARY CANCER; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS; YOUNG ADULT; ZINC FINGERS;

EID: 84863813302     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes033     Document Type: Article

References (32)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
2. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002;28:723-41.
3. Hoshino K, Muro Y, Sugiura K et al. Anti-MDA5 and anti-TIF1-g antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010;49: 1726-33.
4. Oddis CV, Fertig N, Goel A et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis (abstract). Arthritis Rheum 1997;40:S139.
5. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009;36:2547-51.
6. Gunawardena H, Wedderburn LR, Chinoy H et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60:1807-14.
7. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
9. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46:626-36.
10. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
11. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.
12. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Takehara K, Sato S. The classification of pathogenesis and the development of therapy in systemic sclerosis: the classification of severity and the guideline for treatment (2004). A research project for systemic sclerosis supported by the Ministry of Health, Labour and Welfare of Japan (Japanese). Tokyo: Ministry of Health, Labour and Welfare, 2004.
14. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
15. Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for MCTD. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Antinuclear Antibodies. Amsterdam: Elsevier, 1987:33-40.
16. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/ interstitial lung disease during disease remission. Rheumatology 2011. Advance Access published 30 December 2011, doi: 10.1093/rheumatology/ker408.
17. Ogawa Y, Sugiura K, Watanabe A et al. Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 2004;23: 221-31.
18. Okamoto M, Ogawa Y, Watanabe A et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun 2004;23:257-66.
19. Goto N, Sugiura K, Ogawa Y et al. Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies. J Autoimmun 2006;26:42-51.
20. Tanaka N, Muro Y, Sugiura K, Tomita Y. Anti-SS-A/Ro antibody determination by indirect immunofluorescence and comparison of different methods of anti-nuclear antibody screening. Mod Rheumatol 2008;18:585-92.
21. Watanabe A, Kodera M, Sugiura K et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892-900.
22. Pachman LM, Veis A, Stock S et al. Composition of calcification in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum 2006;54:3345-50.
23. Rider LG. Calcinosis in juvenile dermatomyositis: pathogenesis and current therapies. Pediatr Rheumatol Online J 2003;1:119-33.
24. Betteridge ZE, Gunawardena H, Chinoy H et al. Clinical associations of anti-p140 autoantibodies in adult myositis. Ann Rheum Dis 2010;69(Suppl. 3):127.
25. Kimura Y, Sakai F, Nakano O et al. The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem 2002; 277:20611-7.
26. Takahashi K, Yoshida N, Murakami N et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 2007;18:1701-9.
27. Wade PA, Gegonne A, Jones PL et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999;23:62-6.
28. Yan KP, Dolle P, Mark M et al. Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene. Gene 2004; 334:3-13.
29. Betteridge Z, Gunawardena H, North J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007;56:3132-7.
30. Rosendorff A, Sakakibara S, Lu S et al. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci USA 2006;103: 5308-13.
31. Stielow B, Sapetschnig A, Krüger I et al. Identification of SUMO-dependent chromatin-associated transcriptional repression components by a genome-wide RNAi screen. Mol Cell 2008;29:742-54.
32. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS. Recruitment of TIF1g to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 2011;43: 85-96.